Last reviewed · How we verify
umeclidinium bromide (UMEC)
umeclidinium bromide (UMEC) is a Long-acting muscarinic antagonist (LAMA) Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma (in combination with inhaled corticosteroids).
Umeclidinium bromide is a long-acting muscarinic antagonist (anticholinergic) that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow.
Umeclidinium bromide is a long-acting muscarinic antagonist (anticholinergic) that blocks M3 receptors in airway smooth muscle to prevent bronchoconstriction and improve airflow. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma (in combination with inhaled corticosteroids).
At a glance
| Generic name | umeclidinium bromide (UMEC) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Umeclidinium is an inhaled anticholinergic agent that selectively antagonizes muscarinic M3 receptors on airway smooth muscle cells. By blocking acetylcholine-mediated bronchoconstriction, it produces sustained bronchodilation and improves lung function in obstructive airway diseases. Its long duration of action (24 hours) allows once-daily dosing.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma (in combination with inhaled corticosteroids)
Common side effects
- Tremor
- Headache
- Palpitations
- Tachycardia
- Urinary retention
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma (PHASE2)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- umeclidinium bromide (UMEC) CI brief — competitive landscape report
- umeclidinium bromide (UMEC) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about umeclidinium bromide (UMEC)
What is umeclidinium bromide (UMEC)?
How does umeclidinium bromide (UMEC) work?
What is umeclidinium bromide (UMEC) used for?
Who makes umeclidinium bromide (UMEC)?
What drug class is umeclidinium bromide (UMEC) in?
What development phase is umeclidinium bromide (UMEC) in?
What are the side effects of umeclidinium bromide (UMEC)?
What does umeclidinium bromide (UMEC) target?
Related
- Drug class: All Long-acting muscarinic antagonist (LAMA) drugs
- Target: All drugs targeting Muscarinic M3 receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Indication: Drugs for Asthma (in combination with inhaled corticosteroids)
- Compare: umeclidinium bromide (UMEC) vs similar drugs
- Pricing: umeclidinium bromide (UMEC) cost, discount & access